PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Jun 06, 2023

bybhenderson

Research Paper Incorporating ProtoKinetix AAGP® Submitted to Scientific Journal for Publication

Dalton, Ohio, June 6, 2023 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced the submission of a research paper describing cell characterization, graft evaluation, and yield of islet-like cells differentiated from patient-derived iPSCS for the treatment and eventual cure of Type-1 Diabetes for publication in Cell Stem Cell,...Read more

May 04, 2023

byprotokinetixp

How ProtoKinetix Improves Cell Viability Assays in Regenerative Medicine

Regenerative medicine has had a growing interest in health care, in the past several decades. This type of treatment focuses on engineering tissue to repair, restore and regenerate cells with its natural cell regeneration processes. While cell regeneration has many opportunities, it also provides unique challenges, because the cells must be kept alive and in...Read more

Jan 20, 2023

byprotokinetixp

Change a Life. Invest in Retinal Replacement

Patients with progressive degenerative eyesight, have been waiting for a cure. For years retinal replacement has been nothing but a wish. But with protoKinetix (PKTX) lives can be changed. PKTX is a biomedical research and development company leading the way to find cell survival solutions for 20 years. PKTX uses AAGP® (Anti-Aging Glycopeptide), to...Read more

Jul 20, 2022

bybhenderson

ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants

Marietta, Ohio, July 20, 2022 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that the University of Alberta has successfully completed Phase 1 clinical trial enrollment for the treatment of type 1 diabetes in islet cell transplants. The molecule, PKX-001 (AAGP®) successfully achieved, to date, the primary...Read more

Jul 15, 2022

byprotokinetixp

AAGP® | Benefits of AAGP®

Why AAGP is a new method for skin protection

We risk skin damage every time we step into the sun, whether for work, play, or travel. The sun’s UV rays cause inflammation and sunburns, and sustained damage can lead to skin cancer, even death. And while dermatologists plead for everyone, no matter their age, color or gender, to use sunscreen, the truth is that...Read more

Jun 27, 2022

byprotokinetixp

Evolving Cell Therapies with AAGP

Advancements in medical science are making effective treatments more accessible than ever before. In its development of AAGP®, ProtoKinetix is opening the door to new cell therapies, as well as improving the efficacy of existing cell therapies. What is cell therapy? Cell therapy entails the use or transfer of human cells as a treatment for...Read more

Apr 19, 2022

byprotokinetixp

Own the future of anti-aging technology with ProtoKinetix (PKTX)

The world over, there is increased interest in the possibility of extending human longevity. What could our lives look like if we had more control over our cells? If we had more control over disease? The potential is forever captivating. That potential is the leading driver of investment in anti-aging technology companies. As technology advances,...Read more

Jan 14, 2022

bybhenderson

ProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually Only

Marietta, Ohio, January 14, 2022- ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it will hold its Annual General Meeting of the Stockholders of the Company (“AGM”) virtually with no option to attend the AGM in person due to ongoing COVID-19 concerns. As set forth in the...Read more

Jan 14, 2022

byprotokinetixp

ProtoKinetix Announces Annual General Stockholder Meeting - Virtual

Investors in ProtoKinetix, Inc., are invited to attend the annual shareholder meeting at 4 p.m. EST on Feb. 11, 2022. Join the meeting online at http://www.virtualshareholdermeeting.com/PKTX2022.

Nov 23, 2021

bybhenderson

ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease

Marietta, Ohio, November 23, 2021 – ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced that it has selected two formulations of its Anti-Aging Glycopeptide (AAGP®) product to be advanced into preclinical efficacy testing for the topical treatment of dry eye disease and ocular inflammation. The selection follows a...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.